Nara Health raised $14 million to expand its third-party administration platform, focused on streamlining coverage and benefits administration workflows. The round was led by Khosla Ventures, with participation from Long Journey Ventures and Superior Studios. While not a therapeutics R&D event, the funding matters for biotech operators that increasingly depend on patient access, reimbursement workflows, and administrative infrastructure to scale new high-cost therapies and diagnostics. Nara’s platform positioning suggests continued investment in healthcare operations tools that reduce friction from diagnosis through treatment delivery.